STAA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
STAAR Surgical Co (STAA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently trading at a discounted valuation, with positive momentum in its largest market, China, and strong preliminary Q1 revenue exceeding $90M. Despite some financial challenges, the company's growth potential and recent analyst upgrades make it an attractive long-term investment.
The MACD histogram is positive at 0.521, indicating bullish momentum. RSI is neutral at 63.365, and moving averages are converging, suggesting potential price stability. The stock is trading near its pivot level of 23.207, with resistance at 26.17 and 28.001, and support at 20.243 and 18.412.
Preliminary Q1 revenue of over $90M, driven by strong performance in China and the Americas.
Analyst upgrades from Canaccord and Wedbush with increased price targets.
Positive sentiment around the stock's valuation and potential recovery in China.
Recent financial performance shows declining net income and EPS.
Concerns about long-term growth clarity in the China market.
Lack of significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 18.08% YoY to $57.8M, and gross margin improved to 75.68%. However, net income dropped by 46.51% YoY to -$18.3M, and EPS declined by 46.38% YoY to -$0.37.
Recent analyst upgrades include Canaccord raising its price target to $27 and upgrading to Buy, citing strong Q1 revenue and valuation attractiveness. Wedbush also raised its price target to $26, maintaining a Neutral rating. Earlier downgrades from Mizuho and Stifel highlighted concerns about China and near-term growth visibility.
